One Injection Replaces 14,600 Pills. CRISPR Just Entered the $17 Billion Statin Market, and the Math Favors the Shot.

Fourteen thousand six hundred. That is how many pills a typical statin patient swallows over a 40-year treatment course: one tablet every morning, 365 days a year, from the day their doctor writes the prescription until the day they die or give up trying. Most give up. Published data show that between a quarter and half of all patients abandon statin therapy within six months to one year of starting it, and the attrition keeps compounding until, by the ten-year mark, adherence settles at 42%, meaning that for every hundred patients prescribed a lifetime of daily cholesterol control, fewer than half are still taking the pill a decade later. Pills work brilliantly in clinical trials, where nurses count them. They fail quietly in kitchens and medicine cabinets, where nobody does.

CRISPR Therapeutics may have found a way around the kitchen counter entirely, and its implications reach far beyond cholesterol. In a Phase 1 trial published in the New England Journal of Medicine, a single intravenous infusion of CTX310 cut LDL cholesterol by 50% and triglycerides by 55% in patients with refractory dyslipidemia who had already failed on maximally tolerated lipid-lowering therapy. Its treatment works by using CRISPR-Cas9 to permanently switch off the ANGPTL3 gene in liver cells, mimicking a natural mutation that gives its carriers lifelong low cholesterol and lower cardiovascular risk with no apparent adverse consequences.

A two-hour infusion, once, forever. No refills. No morning routine. No adherence to manage, no bottle to open, no prescription to renew, no pharmacist to visit, no copay to resent, no side effect to blame for quitting.

The Numbers Nobody Ran

Every article about CTX310 compares its LDL reduction to statins on a percentage basis. Both land in the 30% to 50% range, and journalists routinely treat them as interchangeable. That comparison is misleading because it assumes the statin patient actually takes the statin; in the real world, they often don't.

Here is the calculation that changes the picture, one that nobody in the coverage of CTX310 appears to have run. Statins deliver an average LDL reduction of roughly 40% with full compliance. Long-term adherence, measured across a decade of prescription-refill data from 34,501 patients, settles at 42%. Multiply the two: the population-level, adherence-adjusted LDL reduction from statins is 0.42 × 40% = 16.8%.

CTX310 delivered a 50% LDL reduction in its trial, and because there is nothing to forget, skip, or stop taking, its adherence rate is 100% by definition. Adherence-adjusted LDL reduction for CTX310 is therefore 50%, and the ratio of 50 to 16.8 yields 2.98. A one-shot therapy that matches statin efficacy on paper delivers roughly three times the real-world LDL lowering at the population level. That superiority is not pharmacological; it is architectural. Remove the human from the compliance loop and the drug gets better because the patient can no longer make it worse.

What Quitting Costs

Statin non-adherence is not an inconvenience. It kills. Reliably, predictably, across every dataset anyone has bothered to assemble. A study of 631 post-stroke patients found that 38.9% discontinued statin therapy, often without any medical reason. Among patients who died within one year of their stroke, 79.3% had stopped taking their statin, compared to 29.9% of survivors. After adjustment, the hazard ratio for all-cause mortality among statin discontinuers was 2.78. A separate analysis of nonadherence and fatal stroke reported odds ratios of 2.04 for stroke death among non-adherent patients, with the risk intensifying sharply in the year before death.

Scale this against the denominator, and the numbers become deeply uncomfortable. Approximately 235 million statin prescriptions are written globally each year, according to lipid-lowering drug market analyses. In the United States alone, an estimated 93 million adults have been prescribed statins. If roughly half abandon treatment within two years, that places tens of millions of people in a higher-risk category for cardiovascular events, a category they entered precisely because they were told they needed treatment but couldn't sustain it.

Cardiovascular disease kills 928,741 Americans per year, according to the American Heart Association. It is the leading cause of death globally at 17.9 million lives annually, a toll so large and so persistent that the medical profession treats it less as a crisis than as weather: inevitable, seasonal in its acute presentations, and addressed primarily through chronic maintenance medications that patients are expected to take every single day for the rest of their lives whether they feel sick or not. Isolating the fraction of those deaths attributable to statin non-adherence is difficult to isolate, but the directional signal from the clinical data is unambiguous: people who stop taking their statins die sooner, and a lot of people stop.

Inside the Trial

The CTX310 trial enrolled 15 adults across sites in Australia, New Zealand, and the United Kingdom, all of whom had uncontrolled hypercholesterolemia, hypertriglyceridemia, or mixed dyslipidemia despite receiving the most aggressive available lipid-lowering therapy their clinicians could prescribe. Mean baseline LDL sat at 154.6 mg/dL and median baseline triglycerides at 192.2 mg/dL. Not untreated. Not non-compliant. Failures. Every pill in the formulary had come up short.

Five dose levels were tested: 0.1, 0.3, 0.6, 0.7, and 0.8 mg/kg of body weight, delivered as a single intravenous infusion. No dose-limiting toxicities related to CTX310 were observed across any of the five dose cohorts. Infusion-related reactions occurred in three patients (20%), including back pain and nausea that resolved with supportive care. One patient had a transient elevation in liver enzymes that peaked at three to five times baseline on day four and returned to normal by day fourteen. One participant died suddenly 179 days after receiving the lowest dose (0.1 mg/kg); the death was deemed unrelated to the therapy by the study's safety monitoring board.

At the highest doses (0.7 and 0.8 mg/kg), ANGPTL3 protein levels fell by 73% to 80%. LDL cholesterol dropped by approximately 50% and triglycerides by 55%, reductions that appeared within the first two weeks and remained stable for at least 60 days, which was the minimum follow-up period, though participants will be monitored for one year with an option for fifteen additional years of surveillance.

"Adherence to cholesterol-lowering therapy is one of the biggest challenges in preventing heart disease," Cleveland Clinic's Steven Nissen said of the results. "Many patients stop taking their cholesterol medications within the first year. The possibility of a one-time treatment with lasting effects could be a major clinical advance."

Why ANGPTL3 and Not HMG-CoA Reductase

Statins work by inhibiting HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway that drives cholesterol synthesis in the liver, and because the inhibition is chemical rather than genetic, it is temporary: miss a dose and the enzyme resumes full-speed production within hours, miss a week and the patient's lipid profile drifts back toward its pre-treatment baseline, miss a month and the cardiovascular risk reduction purchased by the prior prescription essentially evaporates. ANGPTL3 is a different target entirely, and attacking it works through a fundamentally different mechanism. ANGPTL3 inhibits two enzymes, lipoprotein lipase and endothelial lipase, that clear fats from the bloodstream. Disable ANGPTL3 and those clearance enzymes run uninhibited, pulling LDL and triglycerides out of circulation permanently.

Safety comes from human genetics. People born with natural loss-of-function mutations in ANGPTL3 are healthy, have lifelong low lipid levels, and show dramatically lower rates of atherosclerotic cardiovascular disease. Regeneron's monoclonal antibody Evkeeza already targets ANGPTL3, but it requires monthly infusions at an annual cost of approximately $450,000 and is approved only for the rarest form of familial hypercholesterolemia. CTX310 attempts to replicate the natural mutation permanently through a one-time gene edit.

This is a crucial distinction that should not be glossed over: CTX310 does not replace statins pharmacologically, it does not work through the same enzyme pathway, and it does not have anywhere near the same evidence base. What it does replace is the need for chronic daily medication, substituting a permanent genomic change that lasts for the patient's remaining lifetime without any further intervention, refill, or compliance burden. For some patients, particularly those with mixed dyslipidemia who need both LDL and triglyceride reduction, it addresses two problems that previously required two or more drugs.

The Cost Puzzle

CRISPR Therapeutics has not disclosed pricing for CTX310, but the comparables are instructive. Casgevy, the company's approved CRISPR therapy for sickle cell disease, costs approximately $2.2 million per treatment. Gene therapies in general have established a price range of $100,000 to $3.5 million per one-time administration. Even if CTX310 launches at the lower end, the raw cost comparison against generic statins looks grotesque: $100,000 versus $1,200 for a lifetime of generic atorvastatin ($30/year for 40 years).

But the raw comparison ignores three factors. First, the patients in this trial were not responding to cheap statins; they had failed maximally tolerated therapy and still had dangerously high lipid levels. For them, the alternative is not $30/year in generic pills. It is $5,800/year for a PCSK9 inhibitor, $6,500/year for inclisiran, or $450,000/year for evinacumab, all of which require ongoing administration. A $200,000 one-time gene edit breaks even against PCSK9 inhibitors in 34 years and against evinacumab in six months.

Second, non-adherent patients generate hospitalizations. The average cost of a myocardial infarction hospitalization in the United States ranges from $22,000 to $53,000, according to American Heart Association data. A single prevented event can offset a substantial fraction of the gene therapy's cost. Third, lifetime productivity losses from cardiovascular events, including disability and premature death, run into the hundreds of thousands of dollars per patient. Health economics models that incorporate these downstream costs will produce numbers far more favorable to one-time interventions than raw drug-price comparisons suggest.

Limitations

The cautions here are substantial and should not be smoothed over. This was a Phase 1 trial with 15 patients and 60 days of follow-up. Sixty days is not forty years. Whether the ANGPTL3 edit persists without degradation, whether hepatocyte turnover dilutes the effect over decades, whether off-target edits produce consequences invisible at two months but devastating at twenty, none of these questions have answers yet. The one patient death, though judged unrelated, sits inside a denominator of fifteen; larger trials will provide the statistical power to separate signal from noise.

The adherence-adjusted calculation presented above, while directionally sound, simplifies a complex reality. Some non-adherent patients are not taking their statins precisely because their cardiovascular risk is lower; others cycle on and off rather than stopping entirely. The 42% ten-year adherence figure comes from pharmacy refill data, which may overcount true non-adherence. And CTX310's 50% LDL reduction was measured in a refractory population; its performance in statin-naive patients, where the clinical need is lower and the comparator simpler, is unknown.

There is also no cardiovascular outcomes data. Nobody knows whether a 50% LDL reduction via ANGPTL3 knockout translates into the same reduction in heart attacks and strokes as a 50% LDL reduction via statin. The mechanistic pathways differ, and lipid-lowering is not identical to event prevention across all drug classes, as the CETP inhibitor failures demonstrated a decade ago.

The Strongest Case Against

The strongest counterargument is not medical but structural. Generic atorvastatin costs $2.50 per month, carries a half-century safety record documented across millions of patients in dozens of countries, and is backed by decades of randomized outcomes data demonstrating that it prevents heart attacks and strokes at a level of certainty no other cardiovascular drug matches. CTX310 has fifteen patients and sixty days of data. Deploying a permanent, irreversible gene edit to solve an adherence problem that could also be addressed with reminder apps, pill organizers, and better patient-physician communication is using a sledgehammer where a nudge might work.

The nudge has been tried. Tried and tried again. For three decades, healthcare systems have invested in adherence interventions: text message reminders, smart pill bottles with electronic caps that log every opening, pharmacist counseling programs, simplified once-daily dosing regimens, insurance copay reductions to near zero, even mailed-to-your-door prescriptions that eliminate the pharmacy trip entirely. Adherence rates have barely moved. The 40% to 75% first-year discontinuation range reported in community samples in 2006 is essentially unchanged from the range reported in 2019 PALM registry data, despite two decades of adherence technology. If the problem were solvable by making pills easier to remember, it would have been solved already. The problem is that daily medication asks something of humans that many humans, for reasons rational and irrational, will not sustain.

What You Can Do

If you are currently taking a statin and it is working for you, keep taking it. Full stop. CTX310 is years away from FDA approval and must still complete Phase 2 and Phase 3 trials enrolling thousands of patients across multiple years of follow-up before it reaches anything resembling a pharmacy shelf. Do not stop your medication in anticipation of a future gene therapy.

If you have stopped taking your statin because of perceived side effects, talk to your doctor before doing anything else. Research shows that the majority of patients who reinitiate statin therapy after stopping can tolerate it long-term, suggesting that many of the side effects patients attribute to statins actually have other causes; a statin remains the single most cost-effective cardiovascular preventive available in 2026, and the mortality data on discontinuation are stark.

If you are a clinician or health-system administrator: watch the CRISPR cardiovascular pipeline. CTX310 is the most advanced candidate, but Verve Therapeutics is pursuing in vivo base editing of the PCSK9 gene (VERVE-102) and the ANGPTL3 gene, and other programs targeting lipoprotein(a) are in preclinical stages. The economics of a shift from chronic medication to one-time genomic intervention will reshape cardiology budgets, pharmacy benefit structures, and long-term care models within the next decade if any of these trials succeed in Phase 3.

If you are a policymaker: the adherence problem is a policy failure as much as a medical one. The United States spends an estimated $100 to $300 billion annually on avoidable costs from medication non-adherence across all chronic diseases. A technology that eliminates adherence as a variable for the world's most prescribed drug category is not just a pharmaceutical advance; it is an infrastructure event.

The Bottom Line

CTX310 did not outperform statins in a head-to-head trial, and it may never need to, because it demonstrated something that could prove more consequential than raw efficacy: that a permanent, one-time gene edit can achieve the same lipid reductions that daily pills deliver on paper but systematically fail to deliver in practice when distributed across millions of human lives with all their chaos, forgetfulness, skepticism, and inertia. The pharmacological story is about ANGPTL3 and lipid metabolism. The larger story is about the gap between what medicines can do in controlled settings and what they actually achieve when handed to real people. Thirty years. That is how long medicine has tried to close that gap by making pills easier to remember. If CTX310's results hold in larger trials, the answer becomes: stop asking.